Professor Jeremy Hobart
Profiles

Professor Jeremy Hobart

Professor

Clinical Trials & Health Research - Institute of Translational & Stratified Medicine (Faculty of Medicine and Dentistry)

Role

Consultant Neurologist Plymouth Hospitals NHS Trust

Professor of Clinical Neurology and Health Measurement Plymouth University Peninsula Schools of Medicine and Dentistry

Qualifications

Jeremy Hobart BSc PhD FRCP Dip Public Health

 

Dr. Jeremy Hobart is a Consultant Neurologist at Derriford Hospital, and Professor at the Plymouth University Peninsula Schools of Medicine and Dentistry. His clinical sub-specialist interest is the diagnosis and management of people with multiple sclerosis. His medical training was at St Mary’s Hospital Medical School in London, and neurology training was undertaken predominantly at the National Hospital for Neurology and Neurosurgery, Queen Square. He is also President of the South Devon branch of the MS Society.

 

Jeremy Hobart’s research interest is rating scales for measuring health outcomes. His training in health measurement and rating scale science has included a PhD in Psychometrics from the London School of Hygiene and Tropical Medicine (Prof Donna Lamping), and post doctoral attachments to the University of Chicago (Prof Ben Wright) and, more recently, a secondment to Murdoch University Perth, Western Australia (Prof David Andrich) sponsored by a Royal Society of Medicine Ellison-Cliffe Travelling Fellowship. By a combination of chance and design, this training means that Jeremy is one of only a handful of clinicians formally trained in rating scale science. He has led the development of a number of rating scales, has published widely in this area, and holds over £7 million in research grants.Jeremy Hobart is a Consultant Neurologist at Plymouth Hospitals NHS Trust, and Professor in Clinical Neurology and Health Measurement at the Plymouth University Peninsula Schools of Medicine and Dentistry.

Key publications are highlighted

Journals
Articles
Middleton RM, Rodgers WJ, Chataway J, Schmierer K, Rog D, Galea I, Akbari A, Tuite-Dalton K, Lockhart-Jones H & Griffiths D 2018 'Validating the portal population of the United Kingdom Multiple Sclerosis Register' Multiple Sclerosis and Related Disorders 24, 3-10 , DOI
Kapoor R, Ho P-R, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL & Freedman MS 2018 'Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension' The Lancet Neurology 17, (5) 405-415 , DOI
Hobart JC, Hussein D, Yusef T & Murat T 2017 'Testing patient-reported outcome measurement equivalence in multinational clinical trials: An exemplar using the 12-item Multiple Sclerosis Walking Scale' Multiple Sclerosis Journal
Powers JH, Patrick DL, Walton MK, Marquis P, Cano S, Hobart J, Isaac M, Vamvakas S, Slagle A & Molsen E 2017 'Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force' Value in Health 20, (1) 2-14 , DOI
Vermersch P, Hobart J, Dive-Pouletty C, Bozzi S, Hass S & Coyle PK 2016 'Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?' Multiple Sclerosis Journal 23, (4) 604-613 , DOI PEARL
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T 2016 'Brain health: time matters in multiple sclerosis' Multiple Sclerosis and Related Disorders 9, S5-S48 , DOI PEARL
Ofori J, Freeman J, Logan A, Rapson R, Zajieck J, Hobart J & Marsden J 2016 'An investigation of commonly prescribed stretches of the ankle plantarflexors in people with Multiple Sclerosis' Clinical Biomechanics 37, (August) 22-26 , DOI PEARL
Hobart J 2016 'Measuring spinal surgical success: the proportion achieving acceptable symptoms' The Spine Journal 16, (4) S19-S20 , DOI PEARL
Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, Petrillo J, Steiner D & Watson C 2015 'Measuring the Impact of Multiple Sclerosis: Enhancing the Performance of the Msis-29 and Msws-12' Value in Health 18, (7) A709-A710 , DOI
Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, Petrillo J, Steiner D & Watson C 2015 'Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36' Value in Health 18, (7) A713-A713 , DOI
Walton MK, Powers JH, Hobart J, Patrick D, Marquis P, Vamvakas S, Isaac M, Molsen E, Cano S & Burke LB 2015 'Clinical Outcome Assessments: Conceptual Foundation—Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force' Value in Health 18, (6) 741-752 , DOI
Baker K, Barrett L, Playford ED, Aspden T, Riazi A & Hobart J 2015 'Measuring arm function early after stroke: is the DASH good enough?' Journal of Neurology, Neurosurgery & Psychiatry 87, (6) 604-610 , DOI PEARL
Mehta L, McNeill M, Hobart J, Wyrwich KW, Poon J-L, Auguste P, Zhong J & Elkins J 2015 'Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results' Multiple Sclerosis Journal - Experimental, Translational and Clinical 1, 205521731559699-205521731559699 , DOI
Germon T & Hobart J 2015 'People receiving unnecessary treatments: accurate diagnosis is key' BMJ 350, (jun02 26) h2962-h2962 , DOI
Mehta L, McNeill M, Hobart J, Wyrwich K, Poon JL, Auguste P, Zhong J & Elkins J 2015 'Identifying a Minimally Important Change Threshold for The Multiple Sclerosis Walking Scale-12 (MSWS-12)' MULTIPLE SCLEROSIS JOURNAL 21, (6) 813-814 Author Site PEARL
Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, Petrillo J, Steiner D, Chen Y & Watson C 2015 'Measuring Upper Limb Function In Multiple Sclerosis: Enhancing The Abilhand’s Performance' Value in Health 18, (3) A24-A24 , DOI
Barrett L, Cano S, Zajicek J & Hobart J 2015 'Lending a hand: can DASH items help ABILHAND improve manual ability measurement in multiple sclerosis?' Mult Scler 21, (5) 612-621 Author Site , DOI
Germon TJ & Hobart JC 2015 'Definitions, diagnosis, and decompression in spinal surgery: problems and solution' Spine J 15, (3 Suppl) S5-S8 Author Site , DOI
Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D & Miller D 2015 'The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis' Health Technol Assess 19, (12) vii-187 Author Site , DOI
Germon T, Singleton W & Hobart J 2014 'Is NICE guidance for identifying lumbar nerve root compression misguided?' Eur Spine J 23 Suppl 1, S20-S24 Author Site , DOI
Hobart J, Cano S, Baron R, Thompson A, Schwid S, Zajicek J & Andrich D 2013 'Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis' Mult Scler 19, (13) 1773-1783 Author Site , DOI PEARL
Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D & Goris A 2013 'Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis' NATURE GENETICS 45, (11) 1353-+ Author Site , DOI
Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, Gomez Cano M, McManus D, Mallik S & Hobart J 2013 'Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial' Lancet Neurology 2013, 1-9 , DOI
Mechelli R, Umeton R, Policano C, Annibali V, Coarelli G, Ricigliano VAG, Vittori D, Fornasiero A, Buscarinu MC & Romano S 2013 'A “Candidate-Interactome” Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis' PLoS ONE 8, (5) e63300-e63300 , DOI
Barrett LE, Cano SJ, Zajicek JP & Hobart JC 2013 'Can the ABILHAND handle manual ability in MS?' Mult Scler 19, (6) 806-815 Author Site , DOI
Hobart J, Blight AR, Goodman A, Lynn F & Putzki N 2013 'Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS' Neurology 80, (16) 1509-1517 Author Site , DOI
Freeman J, Walters R, Ingram W, Slade A, Hobart J & Zajicek J 2013 'Evaluating change in mobility in people with multiple sclerosis: relative responsiveness of four clinical measures' Mult Scler 19, (12) 1632-1639 Author Site , DOI
Freeman J, Walters R, Ingram W, Slade A, Hobart J & Zajicek J 2013 'Evaluating change in mobility in people with multiple sclerosis: relative responsiveness of four clinical measures' Multiple Sclerosis Journal 1-8 , DOI
Hobart J, Gilkes C, Adams W & Germon T 2013 'Interspinous spacers for lumbar foraminal stenosis: formal trials are justified' Eur Spine J 22 Suppl 1, S47-S53 Author Site , DOI
Posner HB, Cano S, Carrillo MC, Selnes O, Stern Y, Thomas RG, Zajicek J & Hobart J 2013 'Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: A new approach' Alzheimer's & Dementia 9, (1) S56-S60 , DOI
Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J & Alzheimer's Disease Neuroimaging Initiative 2013 'Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods' Alzheimers Dement 9, (1 Suppl) S4-S9 Author Site , DOI
Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J & Alzheimer's Disease Neuroimaging Initiative 2013 'Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory' Alzheimers Dement 9, (1 Suppl) S10-S20 Author Site , DOI
Hobart JC, Cano SJ, Warner TT & Thompson AJ 2012 'What sample sizes for reliability and validity studies in neurology?' J Neurol 259, (12) 2681-2694 Author Site , DOI
Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG & MUSEC Research Group 2012 'Multiple sclerosis and extract of cannabis: results of the MUSEC trial' J Neurol Neurosurg Psychiatry 83, (11) 1125-1132 Author Site , DOI
Zajicek JP, Hobart JC, Slade A, Barnes D, Rickards C & Mattison P 2012 'Multiple Sclerosis and Extract of Cannabis (MUSEC) – a randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sativa for the symptomatic relief of muscle stiffness and pain in multiple sclerosis' Journal of Neurology, Neurosurgery and Psychiatry 83, 1125-1132 Publisher Site , DOI
Bladh S, Nilsson MH, Hariz G-M, Westergren A, Hobart J & Hagell P 2012 'Psychometric performance of a generic walking scale (Walk-12G) in multiple sclerosis and Parkinson's disease' JOURNAL OF NEUROLOGY 259, (4) 729-738 Author Site , DOI
Hobart J 2011 'Multiple Sclerosis Walking Scale (MSWS-12): changes on all items are not equal' MULTIPLE SCLEROSIS JOURNAL 17, S92-S93 Author Site
Hobart J 2011 'Multiple Sclerosis Walking Scale (MSWS-12): exactly what clinical benefits do prolonged-release fampridine responders actually get?' MULTIPLE SCLEROSIS JOURNAL 17, S319-S320 Author Site
McGuigan C, Schapiro R, Putzki N & Hobart J 2011 'Responses to items of the MSWS-12 differ depending on EDSS and the impact of prolonged-release fampridine on walking speed' MULTIPLE SCLEROSIS JOURNAL 17, S473-S474 Author Site
International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CCA, Patsopoulos NA, Moutsianas L, Dilthey A & Su Z 2011 'Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis' Nature 476, (7359) 214-219 Author Site , DOI PEARL
Cano S, Barrett L, Zajicek J & Hobart J 2011 'Dimensionality is a relative concept' Mult Scler 17, (7) 893-894 , DOI
Cano SJ, Barrett LE, Zajicek JP & Hobart JC 2011 'Beyond the reach of traditional analyses: using Rasch to evaluate the DASH in people with multiple sclerosis' Mult Scler 17, (2) 214-222 Author Site , DOI
Riazi A, Porter B, Chataway J, Thompson AJ & Hobart JC 2011 'A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS)' Health Qual Life Outcomes 9, Author Site , DOI PEARL
Cano SJ & Hobart JC 2011 'The problem with health measurement' Patient Prefer Adherence 5, 279-290 Author Site , DOI PEARL
Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T & Hobart JC 2010 'The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts' J Neurol Neurosurg Psychiatry 81, (12) 1363-1368 Author Site , DOI
Zajicek JP, Ingram WM, Vickery J, Creanor S, Wright DE & Hobart JC 2010 'Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort' BMC Neurol 10, Author Site , DOI PEARL
Freeman RG, Cano S, Slade A, Delatycki M, Tai G & Hobart J 2010 'Cross-cultural Comparisons: Lessons from Friedreich's Ataxia' QUALITY OF LIFE RESEARCH 19, 64-65 Author Site
Slade AL, Zajicek JP, Ingram WM, Freeman RG, Cano S & Hobart JC 2010 'Does a Rasch-modified FSS deliver better measurements?' QUALITY OF LIFE RESEARCH 19, 89-89 Author Site
Hobart JC & Cano SJ 2010 'Effect sizes can be misleading: Is it time to change the way we measure change?' QUALITY OF LIFE RESEARCH 19, 41-41 Author Site
Cano SJ & Hobart JC 2010 'Validity in fatigue measurement: complementing quality and quantity' QUALITY OF LIFE RESEARCH 19, 14-14 Author Site
Hobart JC, Cano SJ & Thompson AJ 2010 'Effect sizes can be misleading: is it time to change the way we measure change?' J Neurol Neurosurg Psychiatry 81, (9) 1044-1048 Author Site , DOI
Littleton ET, Hobart JC & Palace J 2010 'Modafinil for multiple sclerosis fatigue: Does it work?' CLINICAL NEUROLOGY AND NEUROSURGERY 112, (1) 29-31 Author Site , DOI
Osmani D, Rajagopalan K & Hobart J 2009 'PND33 LINGUISTIC VALIDATION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS-29) FOR USE IN 29 LANGUAGES' Value in Health 12, (7) A371-A371 , DOI
Cano SJ, Riazi A, Schapira AHV, Cooper JM & Hobart JC 2009 'Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies' Mov Disord 24, (7) 984-992 Author Site , DOI
van der Linden FAH, Kragt JJ, Hobart JC, Klein M, Thompson AJ, van der Ploeg HM, Polman CH & Uitdehaag BMJ 2009 'The size of the treatment effect: do patients and proxies agree?' BMC NEUROLOGY 9, Author Site , DOI PEARL
Posner H, Cano S, Aisen P, Selnes O, Stern Y, Thomas R, Weiner M, Zajicek J, Zeger S & Hobart J 2009 'The ADAS-cog's Performance as a Measure- Lessons from the ADNI study. Part 1 Evaluation using traditional Psychometric Methods AAN' Neurology (72)
Hobart J & Cano S 2009 'Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods' Health Technol Assess 13, (12) iii-177 Author Site , DOI
Cano SJ & Hobart JC 2008 'Watch out, watch out, the FDA are about' Dev Med Child Neurol 50, (6) 408-409 Author Site , DOI
Cano S & Hobart J 2008 'Item response' Psychologist 21, (2)
Cano S & Hobart J 2008 'Taking a lead against evil - Response' PSYCHOLOGIST 21, (2) 169-169 Author Site
Hagell P, Tornqvist AL & Hobart J 2008 'Testing the SF-36 in Parkinson's disease' JOURNAL OF NEUROLOGY 255, (2) 246-254 Author Site , DOI
Hobart JC & Cano SJ 2008 'Rating scales for clinical studies in neurology: challenges and opportunities' US Neurology 4, (1)
Cano SJ, Warner TT, Thompson AJ, Bhatia KP, Fitzpatrick R & Hobart JC 2008 'The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?' Health Qual Life Outcomes 6, Author Site , DOI PEARL
Schrag A, Selai C, Mathias C, Low P, Hobart J, Brady N & Quinn NP 2007 'Measuring health-related quality of life in MSA: the MSA-QoL' Mov Disord 22, (16) 2332-2338 Author Site , DOI
Hobart JC, Cano SJ, Zajicek JP & Thompson AJ 2007 'Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations' Lancet Neurol 6, (12) 1094-1105 Author Site , DOI
Campbell J, Winder R, Richards SH & Hobart J 2007 'Exploring the relationships between provision of welfare benefits advice and the health of elderly people: a longitudinal observational study and discussion of methodological issues' Health Soc Care Community 15, (5) 454-463 Author Site , DOI
Katzenschlager R, Schrag A, Evans A, Manson A, Carroll CB, Ottaviani D, Lees AJ & Hobart J 2007 'Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure' Neurology 69, (6) 555-563 Author Site , DOI
Hobart J 2007 'Measuring outcomes in clinical trials of stroke: time for state-of-the-art clinical trials to reject state-of-the-ark rating scales' JOURNAL OF NEUROLOGY 254, (8) 1119-1119 Author Site , DOI
Cano SJ, Zajicek JP, Thompson AJ & Hobart JC 2007 'Beware all neurologists: The FDA's tough new requirements for rating scale performance are coming to a study near you soon' Journal of Neurology Neurosurgery and Psychiatry 78, (9)
Cano SJ, Thompson AJ, Bhatia K, Fitzpatrick R, Warner TT & Hobart JC 2007 'Evidence-based guidelines for using the short form 36 in cervical dystonia' Movement Disorders 22, (1) 122-126
Cano SJ, Thompson AJ, Bhatia K, Fitzpatrick R, Warner TT & Hobart JC 2007 'Evidence-based guidelines for using the Short Form 36 in cervical dystonia' Mov Disord 22, (1) 122-126 Author Site , DOI
Campbell J, Winder R, Richards SH & Hobart J 2007 'Exploring the relationships between provision of welfare benefits advice and the health of elderly people: a longitudinal observational study and discussion of methodological issues' Health & Social Care in the Community 15, (5) 454-463
Schrag A, Selai C, Mathias C, Low P, Hobart J, Brady N & Quinn NP 2007 'Measuring health-related quality of life in MSA: The MSA-QoL' Movement Disorders 22, (16) 2332-2338
Hobart JH 2007 'Measuring with rating scales - principles of measurements' Multiple Sclerosis 13, S15-S15
van Ter Linden FAH, Kragt JJ, Hobart JH, Klein M, Thompson AJ, van der Ploeg HM, Polman CH & Uitdehaag BMJ 2007 'Proxy measurements in MS: does patient's cognitive impairment influence patient-proxy agreement on disease impact?' Multiple Sclerosis 13, S213-S213
Katzenschlager R, Schrag A, Evans A, Manson A, Carroll CB, Ottaviani D, Lees AJ & Hobart J 2007 'Quantifying the impact of dyskinesias in PD - The PDYS-26: A patient-based outcome measure' Neurology 69, (6) 555-563
Hobart JC, Thompson AJ, Zajicek JP & Cano SJ 2007 'Rating scale responsiveness: Its time to change the way we measure change' Journal of Neurology Neurosurgery and Psychiatry 78, (9)
Hobart JC, Cano SJ, Zajicek JP & Thompson AJ 2007 'Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations' Lancet Neurology 6, (12) 1094-1105
Hobart JC & Cano SJ 2007 'Sample size calculations for evaluating neurological rating scales: How many is enough?' Journal of Neurology Neurosurgery and Psychiatry 78, (9)
Cano SJ & Hobart JC 2007 'Selecting the right rating scale: Do neurologists have to have what they're given or can they get what they need?' Journal of Neurology Neurosurgery and Psychiatry 78, (9)
Cano SJ, Hobart JC, Edwards M, Fitzpatrick R, Bhatia K, Thompson AJ & Warner TT 2006 'CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia' Neurology 67, (12) 2230-2232 Author Site , DOI
Cano SJ, O'Connor RJ, Thompson AJ & Hobart JC 2006 'Exploring disability rating scale responsiveness II: do more response options help?' Neurology 67, (11) 2056-2059 Author Site , DOI
Holland A, O'Connor RJ, Thompson AJ, Playford ED & Hobart JC 2006 'Talking the talk on walking the walk: a 12-item generic walking scale suitable for neurological conditions?' J Neurol 253, (12) 1594-1602 Author Site , DOI
Riazi A, Cano SJ, Cooper JM, Bradley JL, Schapira AHV & Hobart JC 2006 'Coordinating outcomes measurement in ataxia research: do some widely used generic rating scales tick the boxes?' Mov Disord 21, (9) 1396-1403 Author Site , DOI
Schrag A, Selai C, Quinn N, Lees A, Litvan I, Lang A, Poon Y, Bower J, Burn D & Hobart J 2006 'Measuring quality of life in PSP: the PSP-QoL' Neurology 67, (1) 39-44 Author Site , DOI
Chataway JC, Porter D, Heaney D, Riazi, Watt H, Hobart JC & Thompson AJ 2006 'Treating multiple sclerosis relapses at home or in hospital out-patients: a randomised controlled trial of intravenous steroid delivery' Lancet Neurology 7, (5) 565-571
van der Linden FAH, Kragt JJ, Hobart JC, Klein M, Thompson AJ, van der Ploeg HM, Polman CH & Uitdehaag BMJ 2006 'Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life' JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 77, (10) 1157-1162 Author Site , DOI
Hobart, Chataway JC, Heaney D & Porter B 2006 'Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial' The Lancet Neurology 5, (7) 565-571 , DOI
Cano SJ, Hobart JC, Edwards M, Fitzpatrick R, Bhatia K, Thompson AJ & Warner TT 2006 'CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia' Neurology 67, (12) 2230-2232
Riazi A, Cano SJ, Cooper JM, Bradley JL, Schapira AHV & Hobart JC 2006 'Coordinating outcomes measurement in ataxia research: Do some widely used generic rating scales tick the boxes?' Movement Disorders 21, (9) 1396-1403
Warner M, Baron RA, Ingram WM, Vickery PJ, Reilly S, Wright DE, Zajicek JP & Hobart JC 2006 'Does the GHQ-30 leave room for change?' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
Cano SJ, O'Connor RJ, Thompson AJ & Hobart JC 2006 'Exploring disability rating scale responsiveness II: Do more response options help?' Neurology 67, (11) 2056-2059
Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ & Zajicek JP 2006 'Getting the measure of spasticity in MS: The Multiple Sclerosis Spasticity Scale (MSSS-88)' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ & Zajicek JP 2006 'Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88)' Brain 129, 224-234
Chataway J, Porter B, Riazi A, Heaney D, Watt H, Hobart J & Thompson A 2006 'Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial' Lancet Neurology 5, (7) 565-571
Cano SJ, Hobart JC, Hart PE, Kolipara LVP, Schapira AHV & Cooper JM 2006 'International co-operative ataxia rating scale (ICARS): Suitable for clinical practice and treatment trials in Friedreich's ataxia?' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
Ingram WM, Hobart JC, Reilly SM, Vickery PJ, Wright DE & Zajicek JP 2006 'Introducing the south west impact of multiple sclerosis (SWIMS) project: A population-based natural history project to acquire patient-orientated information about the impact of multiple sclerosis' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
Hobart JC, Styles IM, Baron R, Thompson AJ & Andrich D 2006 'Is it Rasch to compare thee on another scale?' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
Baron R & Hobart J 2006 'Laughing all the way to the item bank: How to improve your treatment effect by improving your outcome measurement' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
Baron R, Ingram W, Warner M, Vickery PJ, Wright DE, Zajicek J & Hobart JC 2006 'Meaningless statistics and the illusion of fatigue' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
Baron R, Elashaal A, Germon T & Hobart J 2006 'Measuring outcomes in cervical spine surgery: Think twice before using the SF-36' Spine 31, (22) 2575-2584
Schrag A, Selai C, Quinn N, Lees A, Litvan I, Lang A, Poon Y, Bower J, Burn D & Hobart J 2006 'Measuring quality of life in PSP - The PSP-QoL' Neurology 67, (1) 39-44
Baron RA, Elashaal R, Germon T & Hobart J 2006 'Measuring the outcomes of cervical spine surgery; think twice before using the SF-36?' Spine 31, (22) 2575-2584 , DOI
van der Linden FAH, Kragt JJ, Hobart JC, Klein M, Thompson AJ, van der Ploeg HM, Polman CH & Uitdehaag BMJ 2006 'Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life' Journal of Neurology Neurosurgery and Psychiatry 77, (10) 1157-1162
Hobart JC, Zajicek JP & Thompson AJ 2006 'Rating scales for neurological diseases: Lessons from Rasch analysis' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
Holland A, O'Connor RJ, Thompson AJ, Playford ED & Hobart JC 2006 'Talking the talk on walking the walk - A 12-item generic walking scale suitable for neurological conditions?' Journal of Neurology 253, (12) 1594-1602
Cano SJ, Riazi A, Cooper JM, Schapira AHV & Hobart JC 2006 'The Friedreich's Ataxia impact scale (FAIS) meets the needs of today's clinical studies' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
Nicholas R, Vora A, Hobart JC, Malik O & Reynolds R 2006 'The multiple sclerosis impact scale is sensitive to factors predictive of increasing severity of multiple sclerosis' Multiple Sclerosis 12, S87-S87
Hobart J 2005 'How severe is chronic pain in multiple sclerosis?' NATURE CLINICAL PRACTICE NEUROLOGY 1, (2) 80-81 Author Site , DOI
Cano SJ, Hobart JC, Hart PE, Korlipara LVP, Schapira AHV & Cooper JM 2005 'International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia?' Mov Disord 20, (12) 1585-1591 Author Site , DOI
Nicholl L, Hobart JC, Cramp AFL & Lowe-Strong AS 2005 'Measuring quality of life in multiple sclerosis: not as simple as it sounds' MULTIPLE SCLEROSIS 11, (6) 708-712 Author Site , DOI
Hobart, Riazi A, Styles IM & Thompson AJ 2005 'Getting the measure of spasticity in Multiple Sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS - 89)' Brain 129, (1) 224-234 , DOI
Schrag A, Selai C, Quinn N & Hobart J 2005 'Measuring health-related quality of life in patients with progressive supranuclear palsy' Neurocase 11, (4) 246-249 Author Site , DOI
Freeman JA, Hobart JC, Playford ED, Undy B & Thompson AJ 2005 'Evaluating neurorehabilitation: lessons from routine data collection' J Neurol Neurosurg Psychiatry 76, (5) 723-728 Author Site , DOI
Baron R, Zajicek J, Wright D, Vickery J, Ingram W & Hobart J 2005 'Confounding the confused: is measuring the frequency and severity of cognitive impairment really necessary?' Multiple Sclerosis 11, S68-S68
Baron R, Zajicek J, Wright D, Vickery J, Ingram W, Reilly S & Hobart J 2005 'Confounding the confused: Is measuring the frequency and severity of cognitive impairment really necessary?' Journal of the Neurological Sciences 238, S220-S220
Hobart JC, Andrich D, Zajicek JP & Thompson AJ 2005 'Developing rating scales for multiple sclerosis: lessons from Rasch analysis' Multiple Sclerosis 11, S104-S104
Hobart JC, Zajicek JP & Thompson AJ 2005 'Developing rating scales for neurological diseases: Lessons from Rasch analysis' Journal of the Neurological Sciences 238, S229-S230
Freeman JA, Hobart JC, Playford ED, Undy B & Thompson AJ 2005 'Evaluating neurorehabilitation: lessons from routine data collection' Journal of Neurology Neurosurgery and Psychiatry 76, (5) 723-728
Hobart J, Riazi A, Thompson A, Styles I, Ingram W, Vickery J, Warner M, Fox P & Zajicek J 2005 'Getting the measure of spasticity in MS: the multiple sclerosis spasticity scale' Multiple Sclerosis 11, S104-S104
Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ & Zajicek JP 2005 'Getting the measure of spasticity in MS: The Multiple Sclerosis Spasticity Scale (MSSS-88)' Journal of the Neurological Sciences 238, S229-S229
Chataway J, Porter B, Hobart J, Heaney D, Riazi A & Thompson AJ 2005 'Home or away? A randomised controlled trial of treating acute multiple sclerosis relapses with intravenous steroids' Multiple Sclerosis 11, S181-S181
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R & Thompson AJ 2005 'How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales' Journal of Neurology Neurosurgery and Psychiatry 76, (11) 1539-1543
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R & Thompson AJ 2005 'How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales' Journal of Neurology, Neurosurgery and Psychiatry 76, (11) 1539-1543 , DOI
Hobart J 2005 'How severe is chronic pain in multiple sclerosis?' Nature Clinical Practice Neurology 1, (2) 80-81
Cano SJ, Hobart JC, Hart PE, Korlipara LVP, Schapira AH & Cooper JM 2005 'International Cooperative Ataxia Rating Scale (ICARS): Appropriate for studies of Friedreich's ataxia?' Movement Disorders 20, (12) 1585-1591
Ingram W, Hobart J, Reilly S, Vickery P, Wright D & Zajicek J 2005 'Introducing the South West Impact of Multiple Sclerosis Project: a patient-focused natural history study of multiple sclerosis' Multiple Sclerosis 11, S110-S110
Hobart J, Styles L, Baron R, Thompson A & Andrich D 2005 'Is it Rasch to compare thee on another scale?' Multiple Sclerosis 11, S104-S104
Hobart JC, Styles IM, Baron R, Thompson AJ & Andrich D 2005 'Is it Rasch to compare thee on another scale?' Journal of the Neurological Sciences 238, S221-S221
Baron R & Hobart J 2005 'Laughing all the way to the item bank: how to improve your treatment effect by improving your outcome measurement' Journal of the Neurological Sciences 238, S220-S221
Baron R, Ingram W, Warner M, Vickery J, Wright D, Zajicek J & Hobart J 2005 'Meaningless statistics and the illusion of fatigue measurement' Multiple Sclerosis 11, S68-S68
Schrag A, Selai C, Quinn N & Hobart J 2005 'Measuring health-related quality of life in patients with progressive supranuclear palsy' Neurocase 11, (4) 246-249
Nicholl L, Hobart JC, Cramp AFL & Lowe-Strong AS 2005 'Measuring quality of life in multiple sclerosis: not as simple as it sounds' Multiple Sclerosis 11, (6) 708-712
Cano SJ, Warner TT, Linacre JM, Bhatia KP, Thompson AJ, Fitzpatrick R & Hobart JC 2004 'Capturing the true burden of dystonia on patients: The Cervical Dystonia Impact Profile (CDIP-58)' Neurology 63, (9) 1629-1633 , DOI
Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ & Warner TT 2004 'Patient-based outcomes of cervical dystonia: a review of rating scales' Mov Disord 19, (9) 1054-1059 Author Site , DOI
O'Connor RJ, Cano SJ, Thompson AJ & Hobart JC 2004 'Exploring rating scale responsiveness: does the total score reflect the sum of its parts?' Neurology 62, (10) 1842-1844 Author Site
Carroll C, Hobart J, Fox C, Teare L & Gibson J 2004 'Stroke in Devon: knowledge was good, but action was poor' J Neurol Neurosurg Psychiatry 75, (4) 567-571 Author Site PEARL
Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D & Hobart J 2004 'Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study' Neurology 63, (7) 1245-1250 Author Site
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R & Thompson AJ 2004 'Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome' Health Technol Assess 8, (9) iii-48 Author Site
Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C & Thompson A 2004 'Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite' Mult Scler 10, (1) 41-46 Author Site , DOI
Riazi A, Thompson AJ & Hobart JC 2004 'Self-efficacy predicts self-reported health status in multiple sclerosis' Mult Scler 10, (1) 61-66 Author Site , DOI
Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D & Hobart J 2004 'Cannabis for dyskinesia in Parkinson disease - A randomized double-blind crossover study' Neurology 63, (7) 1245-1250
Cano SJ, Warner TT, Linacre JM, Bhatia KP, Thompson AJ, Fitzpatrick R & Hobart JC 2004 'Capturing the true burden of dystonia on patients - The Cervical Dystonia Impact Profile (CDIP-58)' Neurology 63, (9) 1629-1633
Zajicek J, Thompson A & Hobart J 2004 'Clinical trials in multiple sclerosis - The importance of the outcome measure' Journal of Neurology Neurosurgery and Psychiatry 75, (8)
Hobart J, Cano S, O'Connor R, Kinos S, Heinzlef O, Roullet E, Polman C, Uitdehaag B, McGuigan C & Hutchinson M 2004 'Clinical trials in neurology: Are rating scales stable across European countries?' Journal of Neurology Neurosurgery and Psychiatry 75, (5)
Zajicek J, Thompson A & Hobart J 2004 'Cutting the cost and length of clinical trials - the importance of choosing the right outcome measure' Journal of Neurology 251, 152-153
O'Connor RJ, Cano SJ, Thompson AJ & Hobart JC 2004 'Exploring rating scale responsiveness - Does the total score reflect the sum of its parts?' Neurology 62, (10) 1842-1844
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R & Thompson AJ 2004 'Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome' Health Technology Assessment 8, (9) 1-+
Nicholl L, Hobart J, Dunwoody L, Cramp F & Lowe-Strong A 2004 'Measuring disability in multiple sclerosis: is the Community Dependency Index an improvement on the Barthel Index?' MULTIPLE SCLEROSIS 10, (4) 447-450 Author Site , DOI
Nicholl L, Hobart J, Dunwoody L, Cramp F & Lowe-Strong A 2004 'Measuring disability in multiple sclerosis: is the Community Dependency Index an improvement on the Barthel Index?' Multiple Sclerosis 10, (4) 447-450
Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C & Thompson A 2004 'Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite' Multiple Sclerosis 10, (1) 41-46
Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ & Warner TT 2004 'Patient-based outcomes of cervical dystonia: A review of rating scales' Movement Disorders 19, (9) 1054-1059
Riazi A, Thompson AJ & Hobart JC 2004 'Self-efficacy predicts self-reported health status in multiple sclerosis' Multiple Sclerosis 10, (1) 61-66
Carroll C, Hobart J, Fox C, Teare L & Gibson J 2004 'Stroke in Devon: knowledge was good, but action was poor' Journal of Neurology Neurosurgery and Psychiatry 75, (4) 567-571
Cano SJ, Warner TT, Fitzpatrick R, Bhatia K, Thompson AJ & Hobart JC 2004 'The cervical dystonia impact profile (CDIP-58): A new patient-based rating scale' Journal of Neurology Neurosurgery and Psychiatry 75, (8)
Nicholl L, Hobart J, Cramp F & Lowe-Strong AS 2004 'The Leeds Multiple Sclerosis Quality of Life Scale: a further psychometric evaluation' Multiple Sclerosis 10, (7032) S99-S100
Hobart J 2003 'Rating scales for neurologists' J Neurol Neurosurg Psychiatry 74 Suppl 4, iv22-iv26 Author Site
Hobart J 2003 'Rating scales for neurologists' JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 74, 22-26 Author Site
Riazi A, Hobart JC, Fitzpatrick R, Freeman JA & Thompson AJ 2003 'Socio-demographic variables are limited predictors of health status in multiple sclerosis' J Neurol 250, (9) 1088-1093 Author Site , DOI
Mundy HR, Jones SJ, Hobart JC, Hanna MG & Lee PJ 2003 'A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy' Neurology 61, (4) 528-530 Author Site
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R & Thompson AJ 2003 'Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales' Mult Scler 9, (4) 411-419 Author Site , DOI
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Freeman JA, Jenkinson C, Peto V & Thompson AJ 2003 'Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles' J Neurol Neurosurg Psychiatry 74, (6) 710-714 Author Site
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R & Thompson AJ 2003 'Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12)' Neurology 60, (1) 31-36 Author Site
Edwards SGM, Playford ED, Hobart JC & Thompson AJ 2003 'Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation' Journal of Neurology Neurosurgery and Psychiatry 74, (8)
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R & Thompson AJ 2003 'Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales' Multiple Sclerosis 9, (4) 411-419
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R & Thompson AJ 2003 'Measuring the impact of MS on walking ability - The 12-Item MS Walking Scale (MSWS-12)' Neurology 60, (1) 31-36
Hobart J 2003 'Rating scales for neurologists' Journal of Neurology Neurosurgery and Psychiatry 74, 22-26
Riazi A, Hobart JC, Fitzpatrick R, Freeman JA & Thompson AJ 2003 'Socio-demographic variables are limited predictors of health status in multiple sclerosis' Journal of Neurology 250, (9) 1088-1093
Carroll C, Hobart J, Fox C, Teare L & Gibson J 2003 'Stroke in Devon: The need to translate knowledge into action' Journal of Neurology Neurosurgery and Psychiatry 74, (8)
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Freeman JA, Jenkinson C, Peto V & Thompson AJ 2003 'Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles' Journal of Neurology Neurosurgery and Psychiatry 74, (6) 710-714
Hobart J 2002 'Measuring disease impact in disabling neurological conditions: are patientsʼ perspectives and scientific rigor compatible?' Current Opinion in Neurology 15, (6) 721-724 , DOI
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R & Thompson AJ 2002 'Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples' J Neurol Neurosurg Psychiatry 73, (6) 701-704 Author Site
Hobart J, Riazi A, Lamping D, Fitzpatrick R & Thompson AJ 2002 'Evaluating the use of B-INTERFERON in the UK: From whose perspective?' JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 73, (2) 227-227 Author Site
Edwards SGM, Playford ED, Hobart JC & Thompson AJ 2002 'Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation' BMJ 324, (7352) Author Site
Hobart JC, Williams LS, Moran K & Thompson AJ 2002 'Quality of life measurement after stroke: uses and abuses of the SF-36' Stroke 33, (5) 1348-1356 Author Site
Jenkinson C, Hobart J, Chandola T, Fitzpatrick R, Peto V, Swash M & ALS-HPS Steering Group. Amyotrophic Lateral Sclerosis Health Profile Study 2002 'Use of the short form health survey (SF-36) in patients with amyotrophic lateral sclerosis: tests of data quality, score reliability, response rate and scaling assumptions' J Neurol 249, (2) 178-183 Author Site
Edwards SGM, Playford ED, Hobart JC & Thompson AJ 2002 'Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation' British Medical Journal 324, (7352) 1493-1493
Hobart J, Riazi A, Lamping D, Fitzpatrick R & Thompson AJ 2002 'Evaluating the use of B-INTERFERON in the UK: From whose perspective?' Journal of Neurology Neurosurgery and Psychiatry 73, (2) 227-227
Hobart J 2002 'Measuring disease impact in disabling neurological conditions: are patients' perspectives and scientific rigor compatible?' Current Opinion in Neurology 15, (6) 721-724
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R & Thompson AJ 2002 'Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples' Journal of Neurology Neurosurgery and Psychiatry 73, (6) 701-704
Hobart JC, Williams LS, Moran K & Thompson AJ 2002 'Quality of life measurement after stroke - Uses and abuses of the SF-36' Stroke 33, (5) 1348-1356
Hobart JC, Lamping DL, Freeman JA, Greenwood RJ, McLellan DL & Thompson A 2001 'Evidence-based measurement: which disability scale for neurological rehabilitation?' Neurology 57, 639-644
Hobart J, Freeman J, Lamping D, Fitzpatrick R & Thompson A 2001 'The SF-36 in multiple sclerosis: why basic assumptions must be tested' J Neurol Neurosurg Psychiatry 71, (3) 363-370 Author Site
Hobart JC, Freeman JA, Fitzpatrick R & Thompson A 2001 'The SF-36 in multiple sclerosis: why basic assumptions must be tested' Journal of Neurology, Neurosurgery and Psychiatry 71, (3) 363-370
Hobart JC & Thompson AJ 2001 'The five item Barthel index' J Neurol Neurosurg Psychiatry 71, (2) 225-230 Author Site
Freeman JA, Hobart JC & Thompson AJ 2001 'Does adding MS-specific items to a generic measure (the SF-36) improve measurement?' Neurology 57, (1) 68-74 Author Site
Manson AJ, Katzenschlager R, Hobart J & Lees AJ 2001 'High dose naltrexone for dyskinesias induced by levodopa' J Neurol Neurosurg Psychiatry 70, (4) 554-556 Author Site
Hobart, Freeman JA, Lamping DL & Langdon DW 2001 'Evidence-based measurement: which disability scale for neurologic rehabilitation?' Neurology 57, 639-644
Hobart, Fitzpatrick R, Lamping D & Riazi A 2001 'The multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure' Brain 124, (5) 962-973 , DOI
Hobart 2001 'The multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure' Brain 124 (5), 962-973 , DOI
Hobart J, Freeman J & Thompson A 2000 'Kurtzke scales revisited: the application of psychometric methods to clinical intuition' Brain 123 ( Pt 5), 1027-1040 Author Site
Freeman JA, Hobart JC, Langdon DW & Thompson AJ 2000 'Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis' J Neurol Neurosurg Psychiatry 68, (2) 150-156 Author Site
van der Putten JJ, Hobart JC, Freeman JA & Thompson AJ 1999 'Measuring change in disability after inpatient rehabilitation: comparison of the responsiveness of the Barthel index and the Functional Independence Measure' J Neurol Neurosurg Psychiatry 66, (4) 480-484 Author Site
Freeman JA, Langdon DW, Hobart JC & Thompson AJ 1999 'Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?' Neurology 52, (1) 50-56 Author Site
Thompson AJ & Hobart JC 1998 'Multiple sclerosis: assessment of disability and disability scales' J Neurol 245, (4) 189-196 Author Site
Freeman JA, Langdon DW, Hobart JC & Thompson AJ 1997 'The impact of inpatient rehabilitation on progressive multiple sclerosis' Ann Neurol 42, (2) 236-244 Author Site , DOI
Hobart J & Thompson A 1997 'A comparison of two neurologic scoring instruments for multiple sclerosis' JOURNAL OF NEUROLOGY 244, (1) 60-60 Author Site
Hobart JC, Freeman JA & Lamping DL 1996 'Physician and patient-oriented outcomes in progressive neurological disease: which to measure?' Curr Opin Neurol 9, (6) 441-444 Author Site
Hobart JC, Lamping DL & Thompson AJ 1996 'Evaluating neurological outcome measures: The bare essentials' JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 60, (2) 127-130 Author Site , DOI
Hobart JC, Freeman JA & Lamping DL 1996 'Evaluating outcome measurement instruments' MS Management 1, (2) 6-12
Freeman JA, Langdon DW, Hobart JC & Thompson AJ 1996 'Health-related quality of life in people with multiple sclerosis undergoing inpatient rehabilitation' JOURNAL OF NEUROLOGIC REHABILITATION 10, (3) 185-194 Author Site
Freeman JA, Hobart JC & Thompson AJ 1996 'Outcomes-based research in neurorehabilitation: the need for multidisciplinary team involvement' Disabil Rehabil 18, (2) 106-110 Author Site
Dash P, Hobart J, Malik K, Janmohamed S & Hill-Smith A 1990 'A view from the other side' Health Services Journal 100(5230),
Albrecht P, Bjorna IK, Brassat D, Farrell R, Feys P, Hobart JC, Hupperts R, Linnebank M, Magdic J & Oreja-Guevara C 0 'Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience – report of an expert meeting' Therapeutic Advances in Neurological Disorders PEARL
Kirsch BM, Burke L, Hobart J, Angulo D & Walker PS 0 'The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content' JDD PEARL
Reviews
Hobart JC 2006 'Handbook of Neurological Rating Scales' Journal of Neurology,Neurosurgery and Psychiatry (77)
Chapters
Schrag A, Selai C, Mathias C, Low P, Hobart J & Quinn N 2011 'Measuring quality of life in multiple system atrophy' Quality of Life Measurement in Neurodegenerative and Related Conditions 60-70 , DOI
Schrag A, Hobart J, Selai C, Quinn N, Lees AJ, Litvan I, Lang A, Bower J & Burn D 2011 'Measuring quality of life in progressive supranuclear palsy: The PSP-QoL' Quality of Life Measurement in Neurodegenerative and Related Conditions 52-59 , DOI
Hobart J & Cano S 2011 'Rasch analysis' Quality of Life Measurement in Neurodegenerative and Related Conditions 147-164 , DOI
Hobart J 2011 'The multiple sclerosis impact scale (MSIS-29): Initial development, subsequent revision, lessons learned' Quality of Life Measurement in Neurodegenerative and Related Conditions 24-40 , DOI
Conference Papers
Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G 2018 'International consensus on quality standards for multiple sclerosis care: results from a modified Delphi process' 430-430
Butzkueven H, Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G 2018 '064 Expert consensus on standards for multiple sclerosis care: results from a modified delphi process' A26.2-A26 , DOI
Laverty J, Harford M, Magecha M, Parsons P, Thomas A, Ledsam J, Hobart J, Dennett R & Freeman J 2018 'Investigating referral patterns to Physiotherapy and Occupational Therapy: A clinical audit' 872-872
Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G 2018 'Engaging Multiple Stakeholder Groups in the Development of Standards for Multiple Sclerosis Care: A Modified Delphi Process' 111-112
Gallagher PJ, McGuigan C, Nicholas R, Hobart J, Ford H, Petheram K, Sharrack B, Robertson N, Mazibrada G & Scolding N 2017 'Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis (ANSWERS MS)' 357-358
Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G 2017 'Expert consensus on standards for multiple sclerosis care: results from a modified Delphi process' 469-470
Hobart J, Hupperts R, Linnebank M, Acosta C, McNeill M & Lima G 2017 'Health-related quality of life improved in people with multiple sclerosis who had clinically meaningful changes in walking ability with PR-Fampridine: Post hoc analysis of enhance' 452-452 , DOI
Hendy P, Heerasing N, Walker G, Heap G, Bewshea C, Kennedy N, Goodhand J, Harrower T, Hobart J & Spiers A 2017 'CLINICAL FEATURES OF DEMYELINATION DURING ANTI-TNF THERAPY: PRELIMINARY OUTCOMES OF THE PRED4 STUDY' A159-A159 , DOI
Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman A, Farrell R, Hupperts R, Englishby V, McNeill M & Chang I 2017 'Prolonged-release fampridine demonstrates rapid and sustained clinically meaningful improvements in walking ability over 24 weeks: MSWS-12 responders in the ENHANCE study' 434-435
Hendy P, Heerasing N, Walker G, Heap G, Bewshae C, Kennedy N, Goodhand J, Martin R, Hobart J & Harrower T 2017 'Clinical features of demyelination following anti-TNF alpha therapy' S360-S360
Hobart J, Alexander M, Bowen A, Butzkueven H, Giovannoni G, Kenny T, Kobelt G & Ziemssen T 2017 'Maximizing Brain Health in Multiple Sclerosis: A Quality Improvement Framework' 94-95
Carroll W, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T 2017 'Time Matters in Multiple Sclerosis - International Consensus Recommendations on Diagnosis, Management and Treatment Access' 332-332
Comi G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T 2017 'Time matters in multiple sclerosis international consensus recommendations on diagnosis, management, and treatment access' 142-142
Hobart J, Alexander M, Bowen A, Butzkueven H, Giovannoni G, Kenny T, Kobelt G & Ziemssen T 2016 'Implementing quality recommendations in multiple sclerosis care - a strategic approach to improve brain health' 638-638
Hobart J, Thangavelu K, Hass S, Chowdhury S & Rufi P 2016 'Measuring treatment satisfaction in patients with RMS in the real world: is the TSQM fit for purpose? An evaluation using Teri-PRO study data' 137-137
Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman A, Farrell R, Englishby V, McNeill M, Chang I & Mehta L 2016 'Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study' 833-834
Wu Y, Gandhi SK, Hobart J, Cutter G & Grinspan A 2016 'Assessment of treatment satisfaction in multiple sclerosis: a review of the literature' 684-684
Giovannoni G, Butzkueven H, Costello K, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C & Traboulsee A 2016 'Brain health: time matters in multiple sclerosis - developmental process and objectives of international consensus policy recommendations' 669-670
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Pepper G, Thalheim C, Traboulsee A & Vollmer T 2016 'Time matters in multiple sclerosis-International consensus policy recommendations on diagnosis, management, and treatment access' NP16-NP16
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T 2016 'Time Matters in Multiple Sclerosis - International Consensus Recommendations on Diagnosis, Management and Treatment Access'
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T 2016 'Time Matters in Multiple Sclerosis - International Consensus Recommendations on Diagnosis, Management and Treatment Access'
Hobart J, Cleanthous S, Zajieck J & Cano S 2015 'CONFUSION IN CLINICAL TRIALS OF ALZHEIMER'S DISEASE' e4.137-e4 , DOI
Cano S, Cleanthous S, Kinter E, Hobart J, Marquis P, Petrillo J, Sabatella G & You X 2015 'Measuring the impact of multiple sclerosis: enhancing the MSIS-29's performance' 622-622
Petrillo J, Cadavid D, Cano S, Cleanthous S, Kinter E, Marquis P, Mikol D, Naoshy S, Sabatella G & Steiner D 2015 'Suboptimal disability measurement in multiple sclerosis clinical trials: limitations of existing patient-reported outcomes measures' 341-341
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T 2015 'Time matters in multiple sclerosis - international consensus recommendations on diagnosis, management and access to treatment' 801-802
Ziemssen T, Hobart J, Feys P, Linnebank M, Goodman A, McNeill M, Zhong J & Mehta L 2015 'Long-term efficacy and safety of prolonged-release fampridine treatment in patients with multiple sclerosis: design of the multicentre, randomised, double-blind, placebo-controlled ENHANCE study' 621-621
Pace A, Zajicek J & Hobart J 2014 'RESPONSIVENESS OF MSMSS IN PROGRESSIVE MULTIPLE SCLEROSIS' , DOI
Mehta L, McNeill M, Hobart J, Wyrwich K, Poon JL, Auguste P, Zhong ZJ & Elkins J 2014 'Identifying an important change threshold for the Multiple Sclerosis Walking Scale-12 (MSWS-12)' 410-411
Hobart J, Cano S, Ingram W & Zajicek J 2012 'A new path for the MS Walking Scale: MSWS-12 version 2' 334-335
Hobart JC & Zajicek JP 2012 'Cannabis as a symptomatic treatment for MS: clinically meaningful MUSEC to the stiffness and walking problems of people with MS' 247-247
Hobart JC, Cano SJ, Thompson AJ & Andrich D 2012 'It's time to change the way we measure change: demonstration, explanation, recommendations' 32-32
Zajicek JP 2012 'Results from the Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial' Hobart J; Wright D; Ball S; Nunn A; Vickery J ABN Annual Meeting Brighton 28/05/2012 30/05/2012
Hobart J, Blight A, Lynn F & Putzki N 2011 'The timed 25-foot walk as an outcome measure for clinical trials in multiple sclerosis: further evidence that a 20% change is clinically meaningful' 150-150
Pace A, Hobart JC & Zajicek JP 2010 'PONM01 Measurement of global strength: stable concept, fluid ruler' e60-e61 , DOI
Pace A, Hobart JC & Zajicek JP 2010 'PONM02 Grading strength in manual muscle testing: bespoke works better' e61-e61 , DOI
Hobart J & Andrich D 2010 'RANKIN SCALES FOR MEASURING STROKE OUTCOMES: IS IT TIME TO THROW IN THE TOWEL?' E67-E67 , DOI
Zajicek JP, Cano SJ, Barrett LE & Hobart JC 2010 'Beyond traditional psychometric methods: Can Rasch help the DASH?' 35-35
Pace AA, Hughes RAC, van Schaik IN, Hobart JC & Grp RMCT 2009 'COMBINING SENSORY MODALITIES WITHIN A SENSORY SUM SCORE: ARE WE PICKING UP GOOD VIBRATIONS?' , DOI
Pace AA, Hughes RAC, Van Schaik IN, Hobart JC & Grp RMCT 2009 'MAKING THE MOST OF OLNS DATA: CAN WE GET MORE OUT OF WHAT WE PUT IN?' , DOI
Pace AA, Zajicek JP & Hobart JC 2009 'OVERCOMING THE WEAKNESSES OF A RATING SCALE FOR MEASURING STRENGTH' , DOI
Pace AA, Hughes RAC, van Schaik IN, Hobart JC & Grp RMCT 2009 'RANDOMISED TRIAL OF METHOTREXATE IN CIDP STUDY: DID THE MEASUREMENT OF STRENGTH PROVE TO BE A WEAKNESS?' , DOI
Pace AA, Zajicek JP & Hobart JC 2009 'TOO MUCH OF A GOOD THING: THE UNRELIABILITY OF RELIABILITY STATISTICS' , DOI
Pace AA, Hughes RAC, van Schaik IN, Hobart JC & Grp RMCT 2009 'COMBINING SENSORY MODALITIES WITHIN A SENSORY SUM SCORE: ARE WE PICKING UP GOOD VIBRATIONS?' 115-115
Pace AA, Hughes RAC, van Schaik IN, Hobart JC & Grp RMCT 2009 'MAKING THE MOST OF ONLS DATA: CAN WE GET MORE OUT OF WHAT WE PUT IN?' 116-116
Pace AA, Hughes RAC, van Schaik IN, Hobart JC & Grp RMCT 2009 'RANDOMISED TRIAL OF METHOTREXATE IN CIDP (RMC) STUDY: DID THE MEASUREMENT OF STRENGTH PROVE TO BE A WEAKNESS?' 116-117
Hobart JC, Pace A, Barrett LE, Zajicek JP, Cano SJ & Grp CNR 2008 'Lessons from the Cannabinoids in Multiple Sclerosis (CAMS) Study: part 2-what happens when the Ashworth scale makes the grade2' S281-S282
Pace A, Cano SJ, Barrett LE, Zajicek JP, Hobart JC & Grp CNR 2008 'Lessons front the Cannabinoids in Multiple Sclerosis (CAMS) Study : part 1-did Ashworth's scale make the grade?' S285-S285
Cano SJ, Barrett LE, Pace A, Zajicek JP, Hobart JC & Grp CNR 2008 'Measuring upper limb functioning in multiple sclerosis: is the Disabilities of Arm, Shoulder and Hand (DASH) fit for purpose?' S279-S279
Cano SJ, Posner HB, Moline M, Hurt SW & Hobart JC 2008 'Is the ADAS-cog fit for purpose in clinical trials? Part 1 - basic measurement properties' 32-33
Hobart JC, Posner HB, Moline M, Hurt SW & Cano SJ 2008 'Is the ADAS-cog fit for purpose in clinical trials? Part 2 - examination by AD severity' 33-34
Hobart JH 2007 'Measuring with rating scales - principles of measurements' S15-S15
van Ter Linden FAH, Kragt JJ, Hobart JH, Klein M, Thompson AJ, van der Ploeg HM, Polman CH & Uitdehaag BMJ 2007 'Proxy measurements in MS: does patient's cognitive impairment influence patient-proxy agreement on disease impact?' S213-S213
Cano SJ, Zajicek JP, Thompson AJ & Hobart JC 2007 'Beware all neurologists: The FDA's tough new requirements for rating scale performance are coming to a study near you soon' 1031-1031
Hobart JC, Thompson AJ, Zajicek JP & Cano SJ 2007 'Rating scale responsiveness: Its time to change the way we measure change' 1035-1035
Hobart JC & Cano SJ 2007 'Sample size calculations for evaluating neurological rating scales: How many is enough?' 1026-1027
Cano SJ & Hobart JC 2007 'Selecting the right rating scale: Do neurologists have to have what they're given or can they get what they need?' 1034-1035
van der Linden FAH, Kragt JJ, Hobart JC, van Bon MA, Klein M, Thompson AJ, van der Ploeg HM, Uitdehaag BMJ & Polman CH 2006 'Longitudinal proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of MS on daily life over a period of two years' S86-S87
Nicholas R, Vora A, Hobart JC, Malik O & Reynolds R 2006 'The multiple sclerosis impact scale is sensitive to factors predictive of increasing severity of multiple sclerosis' S87-S87
Warner M, Baron RA, Ingram WM, Vickery PJ, Reilly S, Wright DE, Zajicek JP & Hobart JC 2006 'Does the GHQ-30 leave room for change?' 134-134
Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ & Zajicek JP 2006 'Getting the measure of spasticity in MS: The Multiple Sclerosis Spasticity Scale (MSSS-88)' 131-131
Cano SJ, Hobart JC, Hart PE, Kolipara LVP, Schapira AHV & Cooper JM 2006 'International co-operative ataxia rating scale (ICARS): Suitable for clinical practice and treatment trials in Friedreich's ataxia?' 133-133
Ingram WM, Hobart JC, Reilly SM, Vickery PJ, Wright DE & Zajicek JP 2006 'Introducing the south west impact of multiple sclerosis (SWIMS) project: A population-based natural history project to acquire patient-orientated information about the impact of multiple sclerosis' 131-131
Hobart JC, Styles IM, Baron R, Thompson AJ & Andrich D 2006 'Is it Rasch to compare thee on another scale?' 133-133
Baron R & Hobart J 2006 'Laughing all the way to the item bank: How to improve your treatment effect by improving your outcome measurement' 133-133
Baron R, Ingram W, Warner M, Vickery PJ, Wright DE, Zajicek J & Hobart JC 2006 'Meaningless statistics and the illusion of fatigue' 133-133
Hobart JC, Zajicek JP & Thompson AJ 2006 'Rating scales for neurological diseases: Lessons from Rasch analysis' 137-137
Cano SJ, Riazi A, Cooper JM, Schapira AHV & Hobart JC 2006 'The Friedreich's Ataxia impact scale (FAIS) meets the needs of today's clinical studies' 133-133
Baron R, Zajicek J, Wright D, Vickery J, Ingram W, Reilly S & Hobart J 2005 'Confounding the confused: Is measuring the frequency and severity of cognitive impairment really necessary?' S220-S220
Hobart JC, Zajicek JP & Thompson AJ 2005 'Developing rating scales for neurological diseases: Lessons from Rasch analysis' S229-S230
Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ & Zajicek JP 2005 'Getting the measure of spasticity in MS: The Multiple Sclerosis Spasticity Scale (MSSS-88)' S229-S229
Hobart JC, Styles IM, Baron R, Thompson AJ & Andrich D 2005 'Is it Rasch to compare thee on another scale?' S221-S221
Baron R & Hobart J 2005 'Laughing all the way to the item bank: how to improve your treatment effect by improving your outcome measurement' S220-S221
Baron R, Zajicek J, Wright D, Vickery J, Ingram W & Hobart J 2005 'Confounding the confused: is measuring the frequency and severity of cognitive impairment really necessary?' S68-S68
Hobart JC, Andrich D, Zajicek JP & Thompson AJ 2005 'Developing rating scales for multiple sclerosis: lessons from Rasch analysis' S104-S104
Hobart J, Riazi A, Thompson A, Styles I, Ingram W, Vickery J, Warner M, Fox P & Zajicek J 2005 'Getting the measure of spasticity in MS: the multiple sclerosis spasticity scale' S104-S104
Chataway J, Porter B, Hobart J, Heaney D, Riazi A & Thompson AJ 2005 'Home or away? A randomised controlled trial of treating acute multiple sclerosis relapses with intravenous steroids' S181-S181
Ingram W, Hobart J, Reilly S, Vickery P, Wright D & Zajicek J 2005 'Introducing the South West Impact of Multiple Sclerosis Project: a patient-focused natural history study of multiple sclerosis' S110-S110
Hobart J, Styles L, Baron R, Thompson A & Andrich D 2005 'Is it Rasch to compare thee on another scale?' S104-S104
Baron R, Ingram W, Warner M, Vickery J, Wright D, Zajicek J & Hobart J 2005 'Meaningless statistics and the illusion of fatigue measurement' S68-S68
van der Linden FAH, Kragt JJ, Hobart JH, Klein M, Thompson AJ, van der Ploeg HM, Polman CH & Uitdehaag BMJ 2005 'Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of MS on daily life' S100-S100
Nicholl L, Hobart J, Cramp F & Lowe-Strong AS 2004 'The Leeds Multiple Sclerosis Quality of Life Scale: a further psychometric evaluation' S99-S100
Zajicek J, Thompson A & Hobart J 2004 'Clinical trials in multiple sclerosis - The importance of the outcome measure' 1215-1215
Cano SJ, Warner TT, Fitzpatrick R, Bhatia K, Thompson AJ & Hobart JC 2004 'The cervical dystonia impact profile (CDIP-58): A new patient-based rating scale' 1224-1224
Zajicek J, Thompson A & Hobart J 2004 'Cutting the cost and length of clinical trials - the importance of choosing the right outcome measure' 152-153
Hobart J, Cano S, O'Connor R, Kinos S, Heinzlef O, Roullet E, Polman C, Uitdehaag B, McGuigan C & Hutchinson M 2004 'Clinical trials in neurology: Are rating scales stable across European countries?' 801-801
Edwards SGM, Playford ED, Hobart JC & Thompson AJ 2003 'Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation' 1182-1182
Carroll C, Hobart J, Fox C, Teare L & Gibson J 2003 'Stroke in Devon: The need to translate knowledge into action' 1176-1177
Hobart J 1999 'Use of clinical scales' 27-30
Posters
Barrett LE, Cano SJ, Thompson AJ, Zajicek JP & Hobart JC Barrett LE, Cano SJ, Thompson AJ, Zajicek JP & Hobart JC 0 'Myths about rating scales: There is a magic number of response categories' 0 0 Author Site